WPD PharmaceuticalsInc. announced that it has signed Annex No. 2 into its License Agreement with Wake Forest University Health Sciences. On April 22, 2022 WPD Pharmaceuticals Sp.

z o.o. the Polish subsidiary of the Company, signed Annex No 2. into the License Agreement. Previous to Annex No. 2, WPD signed Annex No.

1 to the License Agreement on June 30, 2019. The original License Agreement with WFUHS has been in place since November 28, 2017, and both WPD and WFUHS have worked collaboratively since then. WPD and WFUHS have confirmed that the Licensed Know-How scope of Annex No.2 is larger than the previous agreement, and concerns information received from WFUHS related to, directly or indirectly, the subject matter of the patent rights or necessary or useful for the development, use or manufacture of the Licensed Products of which a copy is submitted to WPD by WFUHS under the License Agreement.

WPD and WFUHS also confirm that the patent rights also cover US 11,136,367 patent (Appl. No.: 16/704,645) as well as any patent applications or patents claiming priority to this patent, any of its foreign equivalents, any patent issued from that patent, as well as any re-examinations, reissues, substitutes, renewals, extensions thereto, or supplementary protection certificates based thereon.